Works matching IS 11707690 AND DT 2022 AND VI 40 AND IP 6
Results: 6
Modeling the ExAnte Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 6, p. 623, doi. 10.1007/s40273-022-01147-5
- By:
- Publication type:
- Article
Disease-Related Costs Published in The Middle East and North Africa Region: Systematic Review and Analysis of Transferability.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 6, p. 587, doi. 10.1007/s40273-022-01146-6
- By:
- Publication type:
- Article
Evaluating the Individual Healthcare Costs and Burden of Disease Associated with RSV Across Age Groups.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 6, p. 633, doi. 10.1007/s40273-022-01142-w
- By:
- Publication type:
- Article
Target Trial Emulation for Transparent and Robust Estimation of Treatment Effects for Health Technology Assessment Using Real-World Data: Opportunities and Challenges.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 6, p. 577, doi. 10.1007/s40273-022-01141-x
- By:
- Publication type:
- Article
A Comparison of Methods for Identifying Informal Carers: Self-Declaration Versus a Time Diary.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 6, p. 611, doi. 10.1007/s40273-022-01136-8
- By:
- Publication type:
- Article
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 6, p. 601, doi. 10.1007/s40273-021-01112-8
- By:
- Publication type:
- Article